These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 28753870)

  • 21. From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life.
    Hogenhout R; Remmers S; van Slooten-Midderigh ME; de Vos II; Roobol MJ;
    Eur Urol Oncol; 2024 Aug; 7(4):713-720. PubMed ID: 37690917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of early detection of clinically significant prostate cancer (ProScreen): study design and rationale.
    Auvinen A; Rannikko A; Taari K; Kujala P; Mirtti T; Kenttämies A; Rinta-Kiikka I; Lehtimäki T; Oksala N; Pettersson K; Tammela TL
    Eur J Epidemiol; 2017 Jun; 32(6):521-527. PubMed ID: 28762124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
    Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
    JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts.
    Zhou CK; Daugherty SE; Liao LM; Freedman ND; Abnet CC; Pfeiffer R; Cook MB
    Cancer Prev Res (Phila); 2017 Jul; 10(7):410-420. PubMed ID: 28507039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of non-steroidal anti-inflammatory drugs and prostate cancer survival in the Finnish prostate cancer screening trial.
    Veitonmäki T; Murtola TJ; Määttänen L; Taari K; Stenman UH; Tammela TL; Auvinen A
    Prostate; 2015 Sep; 75(13):1394-402. PubMed ID: 26073992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer.
    Roberts RO; Jacobson DJ; Girman CJ; Rhodes T; Lieber MM; Jacobsen SJ
    Mayo Clin Proc; 2002 Mar; 77(3):219-25. PubMed ID: 11888024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Number of Screening Cycles Needed to Reduce Prostate Cancer Mortality in the Finnish Section of the European Randomized Study of Prostate Cancer (ERSPC).
    Pakarainen T; Nevalainen J; Talala K; Taari K; Raitanen J; Kujala P; Stenman UH; Tammela TLJ; Auvinen A
    Clin Cancer Res; 2019 Jan; 25(2):839-843. PubMed ID: 30322875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey.
    Singer EA; Palapattu GS; van Wijngaarden E
    Cancer; 2008 Oct; 113(8):2053-7. PubMed ID: 18780337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allopurinol and the risk of prostate cancer in a Finnish population-based cohort.
    Kukko V; Kaipia A; Talala K; Taari K; Tammela TLJ; Auvinen A; Murtola TJ
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):483-490. PubMed ID: 30696944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer.
    Assel M; Sjöblom L; Murtola TJ; Talala K; Kujala P; Stenman UH; Taari K; Auvinen A; Vickers A; Visakorpi T; Tammela TL; Lilja H
    Eur Urol Focus; 2019 Jul; 5(4):561-567. PubMed ID: 29137895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
    Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
    Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up.
    Osses DF; Remmers S; Schröder FH; van der Kwast T; Roobol MJ
    Eur Urol; 2019 Mar; 75(3):374-377. PubMed ID: 30420254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Villers A; Bessaoud F; Trétarre B; Grosclaude P; Malavaud B; Rebillard X; Iborra F; Daubisse L; Malavaud S; Roobol M; Heijnsdijk EA; de Koning HJ; Hugosson J; Rischmann P; Soulié M
    Prog Urol; 2020 Apr; 30(5):252-260. PubMed ID: 32197936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
    Tabei T; Taguri M; Sakai N; Koh H; Yosida M; Fujikawa A; Nirei T; Tsutsumi S; Ito H; Furuhata S; Kawahara T; Miyoshi Y; Noguchi S; Uemura H; Kobayashi K
    Prostate; 2020 Aug; 80(11):824-830. PubMed ID: 32433780
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statin Use and Prostate Cancer Survival in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Peltomaa AI; Talala K; Määttänen L; Taari K; Tammela TLJ; Auvinen A
    Eur Urol Focus; 2017 Apr; 3(2-3):212-220. PubMed ID: 28753762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.